Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL11658743 | 0.91 | MCHR1 (0.53) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL28238066 | 0.84 | MCHR1 (0.47) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL1586 | 0.79 | GAA (0.62) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL31231738 | 0.79 | GAA (0.62) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL8778830 | 0.78 | ALDH1A1 (0.77) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL7740987 | 0.77 | GAA (0.50) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| Methylene Chloride SCHEMBL7156245 | 0.77 | GAA (0.54) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL3976090 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL6621808 | 0.77 | GAA (0.59) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| Water SCHEMBL6162445 | 0.77 | GAA (0.59) | ALDH1A1CYP2C9CYP2C19CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3735975-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054598-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2020-02-20 | — | — | US | disclosed |
| US-20200038368-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELTED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10285973-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190076395-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2496583-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2334687-B9 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. | 2012-07-19 | — | — | US | disclosed |
| EP-2334687-B1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8080580-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2334687-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011051864-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010023594-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ALDH1A1 993/4885CYP2C9 803/4885CYP2C19 1388/4885 |
| US-10285973-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 875/4885CYP2C9 1855/4885CYP2C19 2465/4885 |
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 875/4885CYP2C9 1855/4885CYP2C19 2465/4885 |
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 875/4885CYP2C9 1855/4885CYP2C19 2465/4885 |
| US-20200054598-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 875/4885CYP2C9 1855/4885CYP2C19 2465/4885 |
| US-20200038368-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELTED DISEASES USING SGLT-2 INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 523/4885CYP2C9 2602/4885CYP2C19 3301/4885 |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 875/4885CYP2C9 1855/4885CYP2C19 2465/4885 |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ALDH1A1 1191/4885CYP2C9 703/4885CYP2C19 1200/4885 |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ALDH1A1 1191/4885CYP2C9 703/4885CYP2C19 1200/4885 |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 847/4885CYP2C9 1848/4885CYP2C19 2458/4885 |
| US-20190076395-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | SLC5A1, SLC5A2, GLP1R | ALDH1A1 641/4885CYP2C9 2007/4885CYP2C19 2276/4885 |
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | SLC5A1, SLC5A2, GLP1R | ALDH1A1 641/4885CYP2C9 2007/4885CYP2C19 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.